Home » Stocks » Urovant Sciences

Urovant Sciences Ltd. (UROV)

Stock Price: $9.12 USD -0.08 (-0.87%)
Updated Jul 14, 2020 12:47 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 280.89M
Revenue (ttm) n/a
Net Income (ttm) -146.75M
Shares Out 30.52M
EPS (ttm) -4.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $9.12
Previous Close $9.20
Change ($) -0.08
Change (%) -0.87%
Day's Open 9.13
Day's Range 9.00 - 9.28
Day's Volume 39,346
52-Week Range 6.55 - 15.98

More Stats

Market Cap 280.89M
Enterprise Value 319.92M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 30.52M
Float 5.47M
EPS (basic) -4.82
EPS (diluted) -4.82
FCF / Share -3.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 918,890
Short Ratio 6.87
Short % of Float 11.57%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 14.26
Revenue n/a
Operating Income -138.97M
Net Income -146.75M
Free Cash Flow -102.85M
Net Cash -39.03M
Net Cash / Share -1.27
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -106.12%
ROE -1,750.72%
ROIC -250.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(159.54% upside)
Current: 9.12
Target: 23.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-139-111-37.00-27.06
Net Income-147-111-37.07-26.97
Shares Outstanding30.4225.1517.122.67
Earnings Per Share-4.82-4.43-2.16-10.10
Operating Cash Flow-102-109-34.09-25.26
Capital Expenditures-0.77-0.59-0.52-
Free Cash Flow-103-110-34.61-25.26
Cash & Equivalents51.6685.607.194.77
Total Debt90.6913.53--
Net Cash / Debt-39.0372.067.194.77
Book Value-58.0174.777.073.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Urovant Sciences Ltd.
Country United Kingdom
Employees 70
CEO James A. Robinson

Stock Information

Ticker Symbol UROV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: UROV
IPO Date September 27, 2018


Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.